The company’s cash and securities nearly equal its market value, meaning investors aren’t paying much for the Covid franchise ...

Nothing about the recent past, present, or foreseeable future seems all that compelling.

BioNTech (BNTX) stock slides as 2026 revenue outlook misses forecasts and a CEO succession begins. Read more here ...

If you are wondering whether BioNTech is starting to look like value after the Covid vaccine boom faded, or if the current ...

BioNTech (NASDAQ: BNTX) swung to a Q4 loss and guided for “lower-than-expected” full-year revenue on Tuesday. But the stock ...

In BioNTech’s search for a new CEO—following the announcement earlier Tuesday that Uğu | Leerink Partners called the departure of BioNTech CEO Uğur Şahin and his wife, and CMO Özlem Türeci, to ...

BioNTech (BNTX) reported upbeat Q4 results and FY26 sales guidance below estimates. Shares gained 7.7% on Wednesday. Analysts have mixed opinions.

An unhealthy combination of factors resulted in an unhealthy day on the stock market for next-generation healthcare company BioNTech (NASDAQ: BNTX). Investors were concerned about the latest top-level ...

The company’s co-founders said they are leaving to start a new mRNA-based company.

BioNTech’s CEO and his fellow co-founder will depart the biopharma by the end of the year to head up a new company focused on ...

Ugur Sahin and Özlem Türeci were instrumental in developing the first COVID-19 vaccine to be approved in the West. Now they ...